micro News and Research

RSS

Air pollution hampers fetal growth

Exposure to common air pollutants and traffic during pregnancy significantly increases the risk of restricted fetal growth, even at levels well below those stipulated in current European Union (EU) air-quality directives, according to one of the largest studies of its kind, published in The Lancet Respiratory Medicine.

17 Oct 2013

House dust mite allergy treatment: an interview with Steve Harris, CEO & Co-founder of Circassia

House dust mite allergy is a surprisingly prevalent problem. Something like 27% of the U.S. population and 20% of the European population are what’s called skin-prick test positive for house dust mites, which is a test for sensitivity to allergens to find out if a person is likely to get that allergy.

15 Oct 2013

Crown Bioscience enters into collaboration with Xstrahl for radiation biology research

Crown Bioscience, Inc., a leading global drug discovery and development service company, today announces that it has entered into a collaboration with Xstrahl Ltd, a leading designer and manufacturer of X-Ray solutions for radiation biology research.

From Xstrahl 15 Oct 2013

Drugs often fail to bring acromegaly under control in routine clinical practice

Over a quarter of UK patients treated for growth hormone-producing tumours do not achieve 'safe' growth hormone levels, according to a 30 year UK multi-centre study of clinical management of the rare disease acromegaly. The findings by the Society for Endocrinology UK Acromegaly Register, published in the November issue of Clinical Endocrinology, show that drugs to control acromegaly often fail to bring the disease completely under control in routine clinical practice.

10 Oct 2013

People without insurance seek new options from insurance marketplaces

For consumers who are seeking insurance through the new law, the marketplace's technical problems have been frustrating, but many remain eager.

4 Oct 2013

First Edition: October 3, 2013

Today's headlines include reports about how the federal and state health exchanges worked on their second day of operations. In the background, the congressional budget stand off continues.

3 Oct 2013

Scientists discover how to quantitatively observe cellular processes taking place on "lab on chip" devices

A team of scientists from The University of Texas at Arlington and MIT has figured out how to quantitatively observe cellular processes taking place on so-called "lab on a chip" devices in a silicon environment.

3 Oct 2013

New agreement to expand scope of research project to evaluate MCT-485 for primary liver cancer

MultiCell Technologies, Inc. is pleased to announce the signing of a new sponsored research agreement with Anand Ghanekar, M.D., Ph.D, of the University Health Network's Toronto General Hospital expanding the scope of the research project to evaluate MCT-485 in animal models for the treatment of primary liver cancer.

2 Oct 2013

ARAMARK event to aid low-income San Diego families caring for disabled family members

With minimal resources stretched to the limit, low-income families living in the heart of San Diego are challenged to provide adequate nutritious food, access to physical activity, and quality healthcare not only for themselves, but also for loved ones who suffer from disabling physical, mental or developmental impairments.

2 Oct 2013

Minimally invasive treatments for lumbar spinal stenosis: an interview with James Corbett, President & Chief Executive Officer of Vertos Medical

Lumbar spinal stenosis (LSS) is a degenerative, age-related narrowing of the lower spinal canal that causes pressure on the nerves, leading to pain and reduced mobility. Symptoms include pain, numbness, or tingling in the lower back, legs, or buttocks, which limits your ability to stand or walk.

30 Sep 2013

Sister stem cells display considerable differences despite having identical DNA

Scientists have used a brand new technique for examining individual stem cells to uncover dramatic differences in the gene expression levels - which genes are turned 'up' or 'down'- between apparently identical 'sister' pairs.

27 Sep 2013

World’s first preclinical Magnetic Particle Imaging (MPI) system announced by Bruker

At the 2013 World Molecular Imaging Congress (WMIC, www.wmicmeeting.org), Bruker today announced the world’s first Magnetic Particle Imaging (MPI) system, an entirely new technology for preclinical imaging. The addition of MPI as a complementary preclinical imaging technique for disease studies, translational research and drug discovery, has significant potential in helping researchers gain new insights into disease processes at the organ, cellular and molecular level.

From Bruker BioSpin Group 19 Sep 2013

Multimodal animal bed introduced by Bruker

Today, at the 2013 World Molecular Imaging Congress (WMIC), Bruker introduces a new multimodal animal bed enabling multiple sequential imaging sessions in preclinical research with robust repositioning between scans, while avoiding unwanted motion of the animal during the investigation. This optimizes results for image fusion, combined processing and evaluation of preclinical research applications requiring multiple imaging modalities across multiple systems.

From Bruker BioSpin Group 19 Sep 2013

Using Serialization to Prevent Counterfeiting in the Pharmaceutical Industry

News-Medical speaks to Sue Miles about the dangers of counterfeit pharmaceutical products and how PCI are reducing the risk of counterfeiting during transit.

From Packaging Coordinators Inc. (PCI) 17 Sep 2013

Wake Forest Baptist conducts $24 million project to accelerate development of new therapies

Whether it's the Ebola virus or Sarin and Ricin, a key to responding to chemical or biological attacks is having effective antidotes at the ready. To accelerate the development of new therapies, Wake Forest Baptist Medical Center's Institute for Regenerative Medicine is leading a unique $24 million federally funded project to develop a "body on a chip" that will be used to develop these countermeasures.

12 Sep 2013

Elevated miR-200 boosts survival of lung, ovarian, renal, triple-negative breast cancer patients

A family of microRNAs (miR-200) blocks cancer progression and metastasis by stifling a tumor's ability to weave new blood vessels to support itself, researchers at The University of Texas MD Anderson Cancer Center report today in Nature Communications.

12 Sep 2013

Improved lung function in patients with moderate asthma severity observed with investigational Tiotropium

Boehringer Ingelheim will present a pooled analysis of new data from the Phase 3 UniTinA-asthma® program at the European Respiratory Society (ERS) Annual Congress 2013 in Barcelona. The data from the individual MezzoTinA-asthma® Phase 3 studies (NCT01340209 and NCT00565266), from which the pooled data are derived, show the addition of tiotropium delivered via the Respimat® inhaler to medium-dose maintenance inhaled corticosteroid (ICS) therapy (defined as 400-800 µg budesonide/day or equivalent) improved lung function and provided sustained bronchodilation over 24 hours in patients with moderate asthma and airflow limitation. Tiotropium is being investigated to determine the medicine’s efficacy in treating asthma patients and is not currently approved for this indication.

11 Sep 2013

Patients with COPD show improvements in lung function with olodaterol

Data from the olodaterol Phase 3 clinical program, presented for the first time at the European Respiratory Society (ERS) Annual Congress 2013 in Barcelona, showed the addition of olodaterol 5 and 10 µg delivered once daily via the Respimat® inhaler provided improvements in lung function in patients with moderate to very severe chronic obstructive pulmonary disease (COPD).

10 Sep 2013

European launch of new version of REVIVE™ SE Thrombectomy Device for treatment of acute ischemic stroke announced by Codman Neuro

Codman Neuro*, part of DePuy Synthes Companies of Johnson & Johnson, announced the European launch of the REVIVE™ SE Thrombectomy Device, a next generation clot removal device offering enhanced navigation through the cerebral vasculature and rapid restoration of blood flow to the brain after an ischemic stroke.

9 Sep 2013

Once-daily COPD portfolio data from Novartis presented at European Respiratory Society (ERS) Annual Congress

Novartis announced new analyses of data for once-daily Ultibro® Breezhaler® (investigational QVA149 - indacaterol 85 mcg/glycopyrronium 43 mcg delivered dose, equivalent to 110 mcg/50 mcg metered dose per capsule), which showed significant improvements in lung function, shortness of breath and health-related quality of life for chronic obstructive pulmonary disease (COPD) patients versus all comparators1,2. These data were part of 39 respiratory abstracts presented at the European Respiratory Society (ERS) Annual Congress in Barcelona, Spain.